Page last updated: 2024-11-07

13-azaprostanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

13-azaprostanoic acid: RN given refers to (1S-trans)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123640
CHEMBL ID9811
SCHEMBL ID7719993
MeSH IDM0078836

Synonyms (17)

Synonym
CBIOL_001997
BIO1_000772
BIO1_001261
BIO1_000283
NCGC00161297-01
13-azaprostanoic acid
71629-07-7
CHEMBL9811
(+/-)13-azaprostanoic acid
BML1-G10
7-[(1s,2s)-2-(heptylamino)cyclopentyl]heptanoic acid
cyclopentaneheptanoic acid, 2-(heptylamino)-, (1s-trans)-
DTXSID80221872
SCHEMBL7719993
13-apa
(+-)-13-azaprostanoic acid
7-((1s,2s)-2-(heptylamino)cyclopentyl)heptanoic acid

Research Excerpts

Dosage Studied

13-azaprostanoic acid (13-APA), a TXA2/endoperoxide receptor antagonist, was pretreated with 5 X 10(-5) M and 2 X 10 (-4) M. The dose-response curve of BPS in the veins was shifted to the right.

ExcerptRelevanceReference
" Exposure to 13-azaprostanoic acid (13-APA), 5 X 10(-5) M and 2 X 10(-4) M, for 20 min caused parallel and dose-related shifts to the right of the dose-response curves generated by all three prostanoids without affecting the contractile responses to KCl, norepinephrine, or 5-hydroxytryptamine or relaxation induced by PGI2."( Antagonism of prostanoid-induced vascular contraction by 13-azaprostanoic acid (13-APA).
Horn, PT; Kohli, JD; LeBreton, GC; Venton, DL,
)
0.75
" By pretreatment with 13-azaprostanoic acid (13-APA), a TXA2/endoperoxide receptor antagonist, the dose-response curve of BPS in the veins was shifted to the right."( The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein.
Ishikawa, M; Namiki, A, 1994
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID157026Tested for effect of plasma containing platelets (PRP) against U-46,619 (1 uM) at 50 uM concentration1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123068Inhibition of cyclooxygenase activity in bovine seminal vesicles assessed as arachodonic acid dependent formation of adenochrome from L-epinephrine at 500 uM1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID1123067Inhibition of ADP-induced primary platelet aggregation in aspirin-treated human platelet-rich plasma at 100 uM after 2 mins by turbidometric method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID1123066Inhibition of 300 uM arachidonate-induced platelet aggregation in human platelet-rich plasma at 10 uM by turbidometric method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID157032Tested for effect of plasma containing platelets (PRP) against arachidonic acid (500 uM) at 50 uM concentration1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123071Inhibition of cyclooxygenase activity in bovine seminal vesicles assessed as arachodonic acid dependent formation of adenochrome from L-epinephrine at concentration of one order of magnitude greater than that necessary for 100% inhibition of platelet aggr1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID157031Tested for effect of plasma containing platelets (PRP) against arachidonic acid (500 uM) at 25 uM concentration1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123064Inhibition of 500 uM arachidonate-induced platelet aggregation in human platelet-rich plasma at 10 uM by turbidometric method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
AID157025Tested for effect of plasma containing platelets (PRP) against U-46,619 (1 uM) at 25 uM concentration1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
2-(6-carboxyhexyl)cyclopentanone hexylhydrazone. A potent and time-dependent inhibitor of platelet aggregation.
AID1123065Inhibition of 400 uM arachidonate-induced platelet aggregation in human platelet-rich plasma at 10 uM by turbidometric method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (91.89)18.7374
1990's2 (5.41)18.2507
2000's1 (2.70)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.51 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (97.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]